Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Evans

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Infectious Diseases|December 6, 2018
Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus)David X Liu, Donna L Perry, Lisa Evans DeWald, et al.
Journal of AOAC International|August 22, 2017
AOAC SMPR 2016.017Richard van Breemen, Joseph M Betz, Lisa Evans, et al.
Plos Neglected Tropical Diseases|July 30, 2019
Inhibition of Ebola Virus by a Molecularly Engineered Banana LectinEvelyn M Covés-Datson, Julie Dyall, Lisa Evans DeWald, et al.
Research Square|January 10, 2024
Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membraneErica Saphire, Zhe Li Salie, Zunlong Ke, et al.
Plos Neglected Tropical Diseases|April 14, 2017
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionElizabeth A Nelson, Julie Dyall, Thomas Hoenen, et al.
Nature Communications|February 3, 2025
Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP<sub>(1,2)</sub> in a position elevated from the virion membraneKathryn M Hastie, Zhe Li Salie, Zunlong Ke, et al.
Microorganisms|April 3, 2021
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In VivoCourtney L Finch, Julie Dyall, Shuang Xu, et al.
The Journal of Infectious Diseases|June 26, 2018
Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell CulturesJulie Dyall, Elizabeth A Nelson, Lisa Evans DeWald, et al.
Early Human Development|March 2, 2026
Corrigendum to "Universal maternal testing for group B streptococcus in late pregnancy: process outcomes and alongside qualitative study for the GBS3 trial" [Early Hum. Dev. 213 (2026) Page 1-5/P106442]Jane P Daniels, Kate F Walker, Lucy Bradshaw, et al.
Early Human Development|December 1, 2025
Universal maternal testing for group B streptococcus in late pregnancy: process outcomes and alongside qualitative study for the GBS3 trialJane P Daniels, Kate F Walker, Lucy Bradshaw, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Infectious Diseases|December 6, 2018
Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus)David X Liu, Donna L Perry, Lisa Evans DeWald, et al.
Journal of AOAC International|August 22, 2017
AOAC SMPR 2016.017Richard van Breemen, Joseph M Betz, Lisa Evans, et al.
Plos Neglected Tropical Diseases|July 30, 2019
Inhibition of Ebola Virus by a Molecularly Engineered Banana LectinEvelyn M Covés-Datson, Julie Dyall, Lisa Evans DeWald, et al.
Research Square|January 10, 2024
Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membraneErica Saphire, Zhe Li Salie, Zunlong Ke, et al.
Plos Neglected Tropical Diseases|April 14, 2017
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionElizabeth A Nelson, Julie Dyall, Thomas Hoenen, et al.
Nature Communications|February 3, 2025
Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP<sub>(1,2)</sub> in a position elevated from the virion membraneKathryn M Hastie, Zhe Li Salie, Zunlong Ke, et al.
Microorganisms|April 3, 2021
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In VivoCourtney L Finch, Julie Dyall, Shuang Xu, et al.
The Journal of Infectious Diseases|June 26, 2018
Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell CulturesJulie Dyall, Elizabeth A Nelson, Lisa Evans DeWald, et al.
Early Human Development|March 2, 2026
Corrigendum to "Universal maternal testing for group B streptococcus in late pregnancy: process outcomes and alongside qualitative study for the GBS3 trial" [Early Hum. Dev. 213 (2026) Page 1-5/P106442]Jane P Daniels, Kate F Walker, Lucy Bradshaw, et al.
Early Human Development|December 1, 2025
Universal maternal testing for group B streptococcus in late pregnancy: process outcomes and alongside qualitative study for the GBS3 trialJane P Daniels, Kate F Walker, Lucy Bradshaw, et al.
Pageof 6